Navigation Links
Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results
Date:8/13/2009

2 million, or $1.09 per share, compared to a net loss of $18.2 million, or $1.23 per share, for fiscal 2008.

Cash, cash equivalents and investments at June 30, 2009 were $5.3 million, compared to $8.4 million at March 31, 2009 and $23.3 million at June 30, 2008. As of June 30, 2009, Cardica had approximately 15.8 million common shares outstanding.

Milestones for Fiscal 2010

Cardica expects to achieve the following milestones over the course of fiscal 2010:

  • Begin selling C-Port(R) X-CHANGEII(TM);
  • Build a sales organization of 25 to 30 total sales representatives, including a direct salesforce, independent distributors and manufacturer's representatives, to support the sales effort for the C-Port and PAS-Port systems;
  • Complete animal testing of the Cardica Microcutter for general and thoracic surgery;
  • Complete tooling of Cardica Microcutter; and
  • Achieve additional milestones under Cardica's agreement with Cook for the development of a closure device for patent foramen ovale.

Financial Guidance for 2010

As Cardica transitions its cardiac surgery business to a small core direct sales force supported by independent distributors and manufacturer's representatives, Cardica is not able to provide product revenue guidance for fiscal 2010. For fiscal 2010, Cardica expects that research and development and sales, general and administrative expenses will total between $11 and $13 million, including non-cash stock-based compensation expense of approximately $1 million. Cardica expects its cash and cash equivalents to decline by approximately $2.5 million per quarter in fiscal 2010, without giving effect to any financing transactions.

Conference Call Details

Cardica's management will host a conference call today, August 13, 2009, at 4:30
'/>"/>

SOURCE Cardica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cardica Announces Proposed Public Offering of Common Stock
2. Cardica Announces Pricing of $34.7 Million Public Offering of Common Stock
3. Cardica Announces Live Webcast Demonstrating Breakthrough Device to Facilitate Beating Heart and Robotic Coronary Revascularization Surgery
4. Cardica Announces Exercise of Over-Allotment Option
5. Cardica to Announce Fiscal 2008 Second Quarter Financial Results on Thursday, January 24, 2008
6. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
7. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
8. Cardica to Announce Fiscal 2008 Third Quarter Financial Results on Tuesday, April 29, 2008
9. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
10. Renowned Leader and Educator in Robotic Cardiac Bypass Surgery Leverages Cardicas C-Port(R) Flex-A(R) Anastomosis System in His Practice and to Educate Cardiothoracic Surgeons
11. Cardica Names Frederick Bauer Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... a colored ribbon representing a disease. A pink ribbon is ... does one think of with lung cancer?, Although white has ... the disease, black may be the only one they think ... patients, primarily smokers between the ages of 51 to 79 ... felt by these patients, the emotional toll it can have ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... eye’s retina is well on its way to offering ... as retinitis pigmentosa and age-related degeneration of the eye ... implant works for eye diseases in which healthy retinal ... eye’s photoreceptors.// These receptors convert images into electric impulses. Researchers ...
... Andhra Pradesh are to have a common e-platform which ... with the inauguration of www.aponline.gov.in, the state government's latest ... departments under one umbrella. The portal is being developed ... joint venture agreement.While TCS is enjoying 89% of the ...
... a common problem for heavy drinkers and the scientist have ... support the potentialities of a night out. ,Researchers at ... Clinic in Minnesota say the effect of alcohol on blood ... of healthy young adults, that blood vessels do not strengthen ...
... as the world's worst pandemic if the 40 million people ... drugs. The illness has killed 25 million people since the ... with HIV, which destroys the immune system. ,Without ... the death toll beyond the 40 million killed// by the ...
... babies suffer from asphyxia, which can lead to brain injury, ... per cent of babies who suffer from a moderate lack ... currently no effective treatments to reduce the risk of asphyxia ... lowering a baby's temperature may have beneficial effects. ,UK ...
... alpha gene are the cause of premature menopause which is ... of the total population. ,The University of Auckland team ... genetic test, which would allow women// with a family history ... They analysed DNA from women who had experienced POF, which ...
Cached Medicine News:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... Omnicell, Inc . (NASDAQ: OMCL ... solutions and analytics software for healthcare facilities, today announced ... medication automation products for clinical use in China. ... Chinese hospitals to access advances in operational improvements similar ...
... N.J., Nov. 28, 2011  Johnson & Johnson (NYSE: JNJ ... Health Care Conference on Tuesday, Nov. 29 th at The ... Ethicon will present in a session scheduled at 8:00 a.m. (Eastern ... and other interested parties by accessing the Johnson & Johnson website ...
Cached Medicine Technology:Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 2Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 3Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 4Omnicell Introduces Groundbreaking Mandarin-Language Medication Automation System for Use in Chinese Clinical Settings 5
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... products are offered as 1-piece or modular, ... modular instruments may be customized with handles ... ratchets, insulation and flush ports. Many standard ... specifications may affect delivery times. , ...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
Medicine Products: